Skip to Content

VESIcare Approval History

  • FDA approved: Yes (First approved November 19th, 2004)
  • Brand name: VESIcare
  • Generic name: solifenacin
  • Dosage form: Tablets
  • Company: Yamanouchi / GlaxoSmithKline
  • Treatment for: Overactive Bladder

VESIcare (solifenacin) is a muscarinic receptor antagonist treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

Development History and FDA Approval Process for VESIcare

Nov 19, 2004Approval Vesicare Yamanouchi / GlaxoSmithKline - Treatment for Overactive Bladder

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.